Efficacy of Combined Treatment with Lanreotide and Cabergoline in Selected Therapy-Resistant Acromegalic Patients

Paolo Marzullo, Diego Ferone, Carolina Di Somma, Rosario Pivonello, Mariagiovanna Filippella, Gaetano Lombardi, Annamaria Colao

Research output: Contribution to journalArticle

Abstract

The aim of this study was to evaluate the efficacy of a 6-month treatment with lanreotide (LAN) (60-90 mg/month) alone and combined with cabergoline (CAB) (1.5-3 mg/week) in 10 acromegalic patients previously demonstrated to be poor responders to octreotide (OCT) (0.6 mg/day) alone and combined with quinagolide (CV) (0.6 mg/day). All patients had previously undergone unsuccessful surgery and none of them received radiotherapy. Immunohistochemistry showed intense positive GH staining in all adenomas, positive PRL staining in 5 adenomas and faint ACTH or FSH/LH positive staining in other 2 adenomas. Moderately elevated serum PRL levels (35 and 47 ng/ml) were recorded in two patients. Fasting plasma IGF-I and serum GH levels were assayed at baseline and 30, 60, 90 and 120 days after each treatment. Gallbladder ultrasonography and sellar MRI were performed before and after 6 months of OCT and LAN treatments. After OCT treatment circulating GH and IGF-I levels remained elevated in all patients, while after 3 months of combined OCT+CV treatment, serum GH levels were suppressed (below 2.5 ng/ml) in only 1 patient. Significant increase of the percent GH (83.9±4.3 vs. 70.3±5.6%, p

Original languageEnglish
Pages (from-to)115-120
Number of pages6
JournalPituitary
Volume1
Issue number2
Publication statusPublished - 1999

Keywords

  • Acromegaly
  • Cabergoline
  • Dopamine-agonists
  • GH
  • IGF-I
  • Lanreotide
  • Octreotide
  • Quinagolide
  • Somatostatin analogs

ASJC Scopus subject areas

  • Endocrinology

Fingerprint Dive into the research topics of 'Efficacy of Combined Treatment with Lanreotide and Cabergoline in Selected Therapy-Resistant Acromegalic Patients'. Together they form a unique fingerprint.

  • Cite this